Cerus Corporation

5.25-0.1800-3.31%Vol 1.70M1Y Perf -10.69%
Aug 11th, 2022 16:00 DELAYED
BID5.20 ASK5.51
Open5.55 Previous Close5.43
Pre-Market- After-Market5.20
 - -  -0.05 -0.95%
Target Price
9.75 
Analyst Rating
Strong Buy 1.00
Potential %
85.71 
Finscreener Ranking
★★★     50.06
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
     41.49
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★+     42.51
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
24.39 
Earnings Rating
Strong Buy
Market Cap929.72M 
Earnings Date
4th Aug 2022
Alpha0.01 Standard Deviation0.14
Beta1.11 

Today's Price Range

5.235.66

52W Range

4.358.06

5 Year PE Ratio Range

-13.00-7.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-5.75%
1 Month
-6.58%
3 Months
7.80%
6 Months
-0.38%
1 Year
-10.69%
3 Years
-1.13%
5 Years
110.84%
10 Years
66.67%

TickerPriceChg.Chg.%
CERS5.25-0.1800-3.31
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
51.40
-25.20
-23.30
-66.40
-25.53
RevenueValueIndustryS&P 500US Markets
135.21M
0.76
24.29
30.13
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.06-0.0516.67
Q01 2022-0.10-0.0730.00
Q04 2021-0.08-0.0537.50
Q03 2021-0.10-0.0730.00
Q02 2021-0.10-0.0910.00
Q01 2021-0.09-0.10-11.11
Q04 2020-0.08-0.09-12.50
Q03 2020-0.12-0.0833.33
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.0614.29Positive
9/2022 QR-0.06-20.00Negative
12/2022 FY-0.286.67Positive
12/2023 FY-0.234.17Positive
Next Report Date-
Estimated EPS Next Report-0.06
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume1.70M
Shares Outstanding177.09K
Shares Float171.15M
Trades Count14.89K
Dollar Volume9.20M
Avg. Volume1.80M
Avg. Weekly Volume2.00M
Avg. Monthly Volume1.46M
Avg. Quarterly Volume1.93M

Cerus Corporation (NASDAQ: CERS) stock closed at 5.25 per share at the end of the most recent trading day (a -3.31% change compared to the prior day closing price) with a volume of 1.70M shares and market capitalization of 929.72M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 270 people. Cerus Corporation CEO is William M. Greenman.

The one-year performance of Cerus Corporation stock is -10.69%, while year-to-date (YTD) performance is -22.91%. CERS stock has a five-year performance of 110.84%. Its 52-week range is between 4.345 and 8.055, which gives CERS stock a 52-week price range ratio of 24.39%

Cerus Corporation currently has a PE ratio of -20.30, a price-to-book (PB) ratio of 12.65, a price-to-sale (PS) ratio of 7.16, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.87%, a ROC of -26.80% and a ROE of -58.96%. The company’s profit margin is -25.53%, its EBITDA margin is -23.30%, and its revenue ttm is $135.21 Million , which makes it $0.76 revenue per share.

Of the last four earnings reports from Cerus Corporation, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. Cerus Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Cerus Corporation is Strong Buy (1), with a target price of $9.75, which is +85.71% compared to the current price. The earnings rating for Cerus Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cerus Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cerus Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 21.09, ATR14 : 0.36, CCI20 : -83.52, Chaikin Money Flow : 0.17, MACD : 0.00, Money Flow Index : 51.62, ROC : 1.50, RSI : 33.66, STOCH (14,3) : 45.65, STOCH RSI : 1.00, UO : 56.44, Williams %R : -54.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cerus Corporation in the last 12-months were: Carol M. Moore (Option Excercise at a value of $482 256), Carol M. Moore (Sold 157 572 shares of value $1 150 302 ), Chrystal Menard (Option Excercise at a value of $0), Chrystal Menard (Sold 30 307 shares of value $152 734 ), Chrystal N. Menard (Option Excercise at a value of $0), Chrystal N. Menard (Sold 30 307 shares of value $152 734 ), Gail Gaumer Schulze (Option Excercise at a value of $71 500), Gail Gaumer Schulze (Sold 25 000 shares of value $188 430 ), Jami Dover Nachtsheim (Option Excercise at a value of $0), Kevin D. Green (Option Excercise at a value of $0), Kevin D. Green (Sold 89 437 shares of value $447 154 ), Laurence M. Corash (Option Excercise at a value of $150 000), Laurence M. Corash (Sold 30 307 shares of value $152 735 ), Richard J. Benjamin (Option Excercise at a value of $0), Richard J. Benjamin (Sold 30 307 shares of value $152 735 ), Timothy L. Moore (Option Excercise at a value of $0), Vivek K. Jayaraman (Option Excercise at a value of $0), Vivek K. Jayaraman (Sold 41 734 shares of value $210 320 ), William M. Greenman (Option Excercise at a value of $1 425 000), William M. Greenman (Sold 308 263 shares of value $1 757 042 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cerus Corporation

Cerus Corp is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East and selected countries in other regions around the world. The firm continues to operate in only one segment: blood safety and generates revenue from the same.

CEO: William M. Greenman

Telephone: +1 925 288-6000

Address: 1220 Concord Avenue, Concord 94520, CA, US

Number of employees: 270

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

60%40%


News

Stocktwits